The role of pituitary and extrapituitary prolactin in reproduction and oncology
More details
Hide details
Katedra i Klinika Ginekologii i Położnictwa Śląskiego Uniwersytetu Medycznego w Katowicach
Klinika Endokrynologii Ginekologicznej Śląskiego Uniwersytetu Medycznego w Katowicach
Corresponding author
Władysław Skałba   

Katedra i Klinika Ginekologii i Położnictwa SUM w Katowicach, ul. Medyków 14, tel. +48 696 460 716
Ann. Acad. Med. Siles. 2016;70:46-50
Prolactin (PRL) acts in the body as a hormone secreted into the blood and as a cytokine. In this review after a brief presentation of the structure of PRL and its receptor, we have focused on local hormone secretion by endometrial and ovarian cancer cells. We have discussed the available information about the autocrine/paracrine hormone signaling pathway in the endometrium and ovary. More attention was focused on the role of PRL in endometrial and ovarian cancers. What is more, the clinical aspects related to the diagnosis and new therapeutic options in these tumors are described. At the end, we have included the suggestion that a number of interesting and important problems of both cancers concerning the pathology and treatment have not yet been discovered, which is a challenge for future research.
Skałba P. Diagnostyka i leczenie zaburzeń endokrynologicznych w ginekologii. Medycyna Praktyczna. Kraków 2014, s. 26–31.
Marano R.J., Ben-Jonathan N. Minireview: Extrapituitary prolactin: An update on the distribution, regulation, and functions. Mol. Endocrinol. 2014; 28: 622–633.
Owerbach D., Rutter W.J., Cooke N.E., Martial J.A., Shows T.B. The prolactin gene is located on chromosome 6 in humans. Science 1981; 212: 815–816.
DiMattia G.E., Gellersen B., Duckworth M.L., Friesen H.G. Human prolactin gene expression.The use of an alternative noncoding exon in decidua and the IM-9-P3 lymphoblast cell line. J. Biol. Chem. 1990; 265: 16412–16421.
Healy D.L. Endometrial prolactin and implantation. Baillieres Clin. Obstet. Gynaecol. 1991; 5: 95–105.
Takashashi H., Nabeshima Y., Ogata K., Takeuchi S. Molecular cloningand nucleotide sequence of DNA complementary to human decidual prolactin mRNA. J. Biochem. 1984; 95: 1491–1499.
Levina V.V., Nolen B., Su Y., Godwin A.K., Fishman D., Liu J., Mor G., Maxwell L.G., Herberman R.B., Szczepanski M.J., Szajnik M.E., Gorelik E., Lokshin A.E. Biological significance of prolactin in gynecological cancers. Cancer Res. 2009; 69: 5226–5233.
Jabbour H.N., Critchley H.O., Boddy S.C. Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase – 2, signal transducer and activator of transcription – 1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin. J. Clin. Endocrinol. Metab. 1998; 83: 2545–2553.
Tanaka S., Koibuchi N., Ohtake H., Ohkawa H., Kawatsu T., Tadokoro N., Kumasaka T., Inaba N., Yamaoka S. Regional comparison of prolactin gene expression in the human decidualized endometrium in early and term pregnancy. Eur. J. Endocrinol. 1996; 135: 177–183.
Bao L., Tessier C., Prigent-Tessier A., Li F., Buzzio O.L., Callegari E.A., Horseman N.D., Gibori G. Decidual prolactin silences the expression the genes detrimental to pregnancy. Endocrinology 2007; 148: 2326–2334.
Eyal O., Jomain J.B., Kessler C., Goffin V., Handwerger S. Autocrine prolactin inhibits human uterine decidualization: a novel role for prolactin. Biol. Reprod. 2007; 76: 777–783.
Clevenger C.V., Kline J.B. Prolactin receptor signal transduction. Lupus 2001; 10: 706–718.
Pickett C.A., Gutierrez-Hartmann A. Epidermal growth factor and Ras regulate gene expresion in GH4 pituitary cells by separate antagonistic signal transduction pathways. Mol. Gell. Biol. 1995; 15: 6777–6784.
Fernandez I., Touraine P., Goffin V. Prolactin and human tumourogenesis J. Neuroendocrinnol 2010; 22: 771–777.
Yeh Y.T., Lee K.T., Tsai C.J., Chen Y.J., Wang S.N. Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J. Surg. 2012; 36: 1128–1135.
Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., Yue L., Bray-Ward P., Ward D.C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005; 102: 7677–7682 .
Chernyshova A.L., Kolomiets L.A., Bochkareva N.V., Kondakova I.V. Specifics of hormonal and energy balance in patients with hyperplasia and endometrial neoplasia with metabolic syndrome in the background. Vopr. Onkol. 2013; 59: 65–71.
Yurkovetsky Z., Ta'asan S., Skates S., Rand A., Lomakin A., Linkov F., Marrangoni A., Velikokhatnaya L., Winans M., Gorelik E., Maxwell G.L., Lu K., Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol. Oncol. 2007; 107(1): 58–65.
Kanat-Pektas M., Yenicesu O., Gungor T., Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch. Gynecol. Obstet. 2010; 281: 709–715.
Clapp C., Thebault S., Macotela Y., Moreno-Carranza B., Triebel J., Martínez de la Escalera G. Regulation of blood vessels by prolactin and vasoinhibins. Adv. Exp. Med. Biol. 2015; 846: 83–95.
Yang X., Meyer K., Friedl A. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J. Biol. Chem. 2013; 288: 21184–21196.
Yang X., Friedl A. A Positive Feedback Loop Between Prolactin and STAT5 Promotes Angiogenesis. Adv. Exp. Med. Biol. 2015; 846: 265–280.
Yamazawa K., Matsui H., Seki K., Sekiya S. A case – control study of endometrial cancer after antipsychotics exposure in premenopausal women. Oncology 2003; 64: 116–123.
Yoshida M., Watanabe G., Suzuki T. Inoue K., Takahasi M., Maekawa A., Taya K., Nishikawa A. Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats. J. Reprod. Dev. 2009; 55: 105–109.
Freeman M.E., Kanyicska B., Lerant A., Nagy G. Prolactin structure, function, and regulation of secretion. Physiol. Rev. 2000; 80: 1523–1631.
Schwärzler P., Untergasser G., Hermann M., Dirnhofer S., Abendsstein B., Berger P. Prolactin gene expression and prolactin protein in premenopausal and postmenopausal human covaries. Fertil. Steril. 1997; 68: 696–701.
Phelps J.Y., Bugg E.M., Shamblott M.J., Vlahos N.P., Whelan J., Zacur H.A. Prolactin gene expression in human ovarian follicular cells. Fertil. Steril. 2003; 79: 182–185.
Erdmann S., Ricken A., Merkwitz C., Struman I., Castino R., Hummitzsch K., Gaunitz E., Isidoro C., Martial J., Spanel-Borowski K. The expression of prolactin and cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E1365–E1377.
Bouilly J., Sonigo C., Auffret J., Gibori G., Binart N. Prolactin sygnalising mechanism in ovary. Mol. Cell. Endocrinol. 2012; 356: 80–87.
Yoshimura Y., Hosoi Y., Iritani A., Nakamura Y., Atlas S.J., Wallach E.E. Developmental potential of rabbit oocyte matured in vitro: the possible contribution of prolactin. Biol. Reprod. 1989; 41: 26–33.
Seibell M.M., Smith D., Długi A.M., Levesque L. Periovulatory follicular fluid hormone levels in spontaneous human cycles. J. Clin. Endocrinol. Metab. 1989; 68: 1073–1077.
Lu D., Kuhn E., Bristow R.E., Giuntoli R.L. 2nd, Kjaer S.K., Shih le.M., Roden R.B. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol. Oncol. 2011; 122: 560–566.
Pils D., Tong D., Hager G., Obermayr E., Aust S., Heinze G., Kohl M., Schuster E., Wolf A., Sheouli J., Braicu I., Vergole I., Van Gorp T., Mahners S., Concin N., Speiser P., Zeillinger R. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. BMC Cancer 2013; 13: 178. doi: 10.1186/1471-2407-13-178.
Nick A.M., Sood A.K. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat. Clin. Pract. Oncol. 2008; 5: 568–569.
Mrochem J., Sodowski K., Deja R., Walaszek-Gruszka A., Wojcieszek A., Kołosza Z., Chmura A., Czernik E., Masłyk B., Bartnik W., Cnota W. Evaluation of selected serum protein markers as early detectors of ovarian cancer. Ginekol. Pol. 2008; 79: 271–275.
Clenden T.V., Arslan A.A., Lokshin A.E., Liu M., Lundin E., Koenig K.L., Berrino F., Hallmans G., Idahl A., Krogh V., Lukanova A., Marrangoni A., Muti P., Nolen B.M., Ohlson N., Shore R.E., Sieri S., Zeleniuch-Jacquotte.
A. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control 2013 ; 24: 741–748.
Tan D., Chen K.E., Khoo T., Walker A.M. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Cancer Lett. 2011; 310: 101–108.
Asai-Sato M., Nagashima Y., Miyagi E., Sato K., Ohta I., Vonderhaar B.K., Hirahara F. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int. J. Cancer. 2005; 115: 539–544.
Wen Y., Zand B., Ozpolat B., Szczepanski M.J., Lu C., Yuca E., Carroll A.R., Alpay N., Bartholomeusz C., Tekedereli I., Kang Y., Rupaimoole R., Pecot C.V., Dalton H.J., Hernandez A., Lokshin A., Lutgendorf S.K., Liu J., Hittelman W.N., Chen W.Y., Lopez-Berestein G., Szajnik M., Ueno N.T., Coleman R.L., Sood A.K. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell. Rep. 2014; 7(2): 488–500.
Journals System - logo
Scroll to top